Amgen, J&J settle sales-discount lawsuit

Amgen agreed to pay $200 million to settle an antitrust lawsuit by Johnson & Johnson's Ortho Biotech unit, putting to rest 2½ years of legal wrangling over Amgen's sales of its oncology products Aranesp, Neupogen, and Neulasta. Report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.